Myriad Genetics, Biogen, Moderna, and Microsoft are discussed as peers in the therapeutics segment and are mentioned in thematic investing contexts.
1 report, 1 independent
Updated Aug 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Myriad Genetics, Biogen, Moderna, and Microsoft are discussed as peers in the therapeutics segment and are mentioned in thematic investing contexts.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Biogen's strong results hint at market expectations for BioMarin, positioning them as peers in the therapeutics segment.Sub-event
Myriad Genetics, Biogen, Moderna, and Microsoft are peers in the therapeutics sector and are relevant to thematic investing.1 source
Keep exploring
The entities involved
-
Myriad Genetics
American biotechnology company
-
Biogen
American multinational biotechnology company
Nothing else this week.
-
Moderna
American biotechnology company
-
Microsoft
American multinational technology corporation
- Nvidia is expanding its platform deployment across major cloud providers, including Google Cloud and Microsoft Azure.
- Cloud giants, including Microsoft, Amazon, Anthropic, OpenAI, and Google, are benefiting from overall AI market growth while navigating corporate cost containment and future market competition.
Coverage
Newest first; wire copies grouped- StockStoryEarnings To Watch: Myriad Genetics (MYGN) Reports Q2 Results Tomorrow Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be announcing earnings results this Tuesday after market hours. Here’s